Postdoctoral Scholar, Therapeutics Discovery

Purpose: The Scholar will work closely with teams employing bioconjugate chemistry and protein engineering toward the discovery of antibody drug conjugates (ADCs) and related modalities.

You will be responsible for:

• Implement new project ideas (design and execution of studies, analysis of data, presentation of results).
• Collaborate with team members and other groups to advance the projects.
• Keep abreast of new technologies/capabilities relevant to this role and strive to implement them to advance research projects.
• Author data summaries, publications, and presentations.

Education: Minimum of a PhD in Biochemistry, Chemical/Biomedical Engineering, Molecular Biology, Chemistry, or other related field is required.

Experience / Skills

• Experience with display technology is required.
• Familiarity with antibody structure and function, experience in antibody engineering and/or antibody drug conjugates preferred
• Experience with protein biochemistry, protein expression, protein purification, bioconjugation methods, and/or biophysical characterization is preferred
• Experience with biomolecule purification using automated chromatography systems is preferred.
• Applicant should be organized, self-motivated and capable of working independently, as well as in a collaborative multi-disciplinary environment.
• Interest and ability to work in a dynamic, fast-paced environment, and capable of handling multiple tasks
• A solid research record demonstrated by publications and/or presentations.
• Excellent oral and written communication skills.

Johnson & Johnson is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, age, national origin, disability, protected veteran status or other characteristics protected by federal, state or local law. We actively seek qualified candidates who are protected veterans and individuals with disabilities as defined under VEVRAA and Section 503 of the Rehabilitation Act.